← Back to Clinical Trials
Recruiting NCT05415007

NCT05415007 GOLD: Brief Intervention to Reduce Anxiety and Promote Resilience in Families of Youth With Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05415007
Status Recruiting
Phase
Sponsor Stanford University
Condition Cancer
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2022-09-21
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 8 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
GOLD ProgramTreatment as usual (TAU)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2022-09-21 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to examine a psychotherapeutic and psycho-educational intervention offered in virtual settings to caregivers of youth with cancer. Human subjects must be used because they are the object of the intervention.

Eligibility Criteria

Inclusion and Exclusion Criteria: Parents Inclusion * Child (0-17yrs) with recent (\<12 mo) cancer diagnosis * Fluent in English * Consent to research Exclusion: * Lack of proficiency in written and spoken English * Parent is under age 18 * Active Suicidal Ideation * Child with cancer does not provide assent Inclusion and Exclusion Criteria: Children Inclusion: * Recent (\<12 mo) cancer diagnosis in child * 8-17 Years old * Provides assent to participate in the study Exclusion: * Cannot read English * Parent is not enrolled in the study Anyone who is not a caregiver of children who have been diagnosed with cancer within the past 12 months will be excluded.

Contact & Investigator

Central Contact

Victoria E. Cosgrove, PhD

✉ veileen@stanford.edu

📞 650-995-6848

Principal Investigator

Victoria E. Cosgrove, PhD

PRINCIPAL INVESTIGATOR

Stanford University

Frequently Asked Questions

Who can join the NCT05415007 clinical trial?

This trial is open to participants of all sexes, aged 8 Years or older, up to 18 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05415007 currently recruiting?

Yes, NCT05415007 is actively recruiting participants. Contact the research team at veileen@stanford.edu for enrollment information.

Where is the NCT05415007 trial being conducted?

This trial is being conducted at San Francisco, United States.

Who is sponsoring the NCT05415007 clinical trial?

NCT05415007 is sponsored by Stanford University. The principal investigator is Victoria E. Cosgrove, PhD at Stanford University. The trial plans to enroll 40 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology